Eisai enters into agreement with Blissbio for antibody-drug conjugate BB-1701
Based on the status of Phase I/II clinical trials of BB-1701 currently being conducted by BlissBio, both companies have decided to…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.